333 related articles for article (PubMed ID: 23529930)
1. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
[TBL] [Abstract][Full Text] [Related]
2. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
5. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.
Yin J; Leavenworth JW; Li Y; Luo Q; Xie H; Liu X; Huang S; Yan H; Fu Z; Zhang LY; Zhang L; Hao J; Wu X; Deng X; Roberts CW; Orkin SH; Cantor H; Wang X
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15988-93. PubMed ID: 26668377
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
7. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells.
Tamgue O; Chai CS; Hao L; Zambe JC; Huang WW; Zhang B; Lei M; Wei YM
Asian Pac J Cancer Prev; 2013; 14(10):5663-9. PubMed ID: 24289559
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype.
Ng SB; Ohshima K; Selvarajan V; Huang G; Choo SN; Miyoshi H; Shimizu N; Reghunathan R; Chua HC; Yeoh AE; Quah TC; Koh LP; Tan PL; Chng WJ
Leuk Lymphoma; 2015; 56(8):2408-15. PubMed ID: 25382618
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
12. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
14. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
[TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
17. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Asangani IA; Ateeq B; Cao Q; Dodson L; Pandhi M; Kunju LP; Mehra R; Lonigro RJ; Siddiqui J; Palanisamy N; Wu YM; Cao X; Kim JH; Zhao M; Qin ZS; Iyer MK; Maher CA; Kumar-Sinha C; Varambally S; Chinnaiyan AM
Mol Cell; 2013 Jan; 49(1):80-93. PubMed ID: 23159737
[TBL] [Abstract][Full Text] [Related]
19. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.
Li B; Yan J; Phyu T; Fan S; Chung TH; Mustafa N; Lin B; Wang L; Eichhorn PJA; Goh BC; Ng SB; Kappei D; Chng WJ
Blood; 2019 Dec; 134(23):2046-2058. PubMed ID: 31434700
[TBL] [Abstract][Full Text] [Related]
20. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]